Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings reveal that NORAD/miR-608/STAT3 axis is pivotal in mediating the antineoplastic impacts of PG on ovarian cancer cells, which may offer a novel explanation in the therapy of ovarian cancer.
|
31299866 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.
|
30622051 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Less is known about the role of LIF, which can similarly activate STAT3, in ovarian cancer.
|
30305729 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knockdown of HE4 suppresses aggressive cell growth and malignant progression of ovarian cancer by inhibiting the JAK/STAT3 pathway.
|
31477564 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study proved for the first time that miR-519a functions as a tumor suppressor by targeting STAT3 in ovarian cancer, suggesting that miR-519a may be a potential biomarker for the diagnosis and treatment of ovarian cancer.
|
29434770 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, these compounds may serve as candidate compounds for further modification and development as anticancer therapeutics targeting the DBD of human STAT3 for treatment of cisplatin-resistant ovarian cancer.
|
30145375 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, phosphorylated-Stat3 (Tyr705) amounts OC cell invasion and migration, and expression of matrix metalloproteinases (MMP-9 and MMP-2) decreased.
|
30182276 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
STAT3 regulated <i>miR-216a</i> promotes ovarian cancer proliferation and cisplatin resistance.
|
30061175 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
|
29930760 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.
|
28983974 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activation of JAK2/STAT3 pathway had significant impact on survival of ovarian cancers, especially for the cases with clear-cell histology.
|
29545902 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Our study demonstrated that FEZF1-AS1 exerted an oncogenic role in ovarian cancer via modulating JAK-STAT3 pathway.
|
30416194 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intriguingly, we demonstrated that M-MDSC could be readily induced by ascitic fluids (AF) from OC patients, which was predominantly dependent on IL-6, IL-10 and STAT3 activation as neutralization of IL-6 and/or IL-10 or inhibition of STAT3 abrogated MDSC's expansion while recombinant IL-6 and IL-10 recapitulated the expansive effect of AF; furthermore, predominantly elevated levels of IL-6 and IL-10 has been noted in the AF which was positively correlated with the abundance of M-MDSC as well as poor prognosis of OC patients.
|
29100353 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
|
28209618 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.
|
27292260 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer.
|
28188387 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggest that the phosphorylation of STAT3 regulates MMP-9 production in ovarian cancer, which might be responsible for its invasiveness and metastasis.
|
28859117 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Follow-up was performed to explore relationship of HER2, SOCS3, and STAT3 expressions with survival time of OC patients.
|
28448787 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway.
|
27981892 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, anti-miR551b reduced STAT3 expression in ovarian cancer cells in vitro and in vivo and reduced ovarian cancer growth in vivo.
|
27160903 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further demonstrated that a STAT3/JAK2 inhibitor could potently sensitize platinum-resistant cells to carboplatin and suppress their growth in vivo Our findings offer a mechanistic rationale to target the PBX1/STAT3 axis to antagonize a key mechanism of chemoresistance in ovarian cancers and possibly other human cancers.
|
27590741 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
|
26983899 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Results of the present study suggested that combined therapy with eukaryotic co-expression of the plasmid‑carrying STAT3-specific siRNA and LKB1 is a novel and efficient treatment strategy for human ovarian cancer.
|
25420630 |
2015 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results offer preclinical proof-of-concept for HO-3867 as a selective STAT3 inhibitor to treat ovarian cancer and other solid tumors where STAT3 is widely upregulated.
|
24590057 |
2014 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
JAK/STAT3 is one of the major signaling pathways that is aberrantly activated in ovarian cancer and associated with tumor progression and poor prognosis in patients with ovarian cancer.
|
25319391 |
2014 |